Meta-Analysis
Copyright ©The Author(s) 2023.
World J Methodol. Jun 20, 2023; 13(3): 153-165
Published online Jun 20, 2023. doi: 10.5662/wjm.v13.i3.153
Table 4 Tumor and treatment characteristics, n (%)
Necrosis
Hemorrhage
Mitotic count
Tumor size
Pcna index
Cell type
Treatment
Ref.
Yes
No
Yes
No


≤ 10%
> 10%
Epithelioid
Spindle
Mixed
Surgery
Surgery type
Chemotherapy
Chemotherapy type
Chen et al[22] 23 (37)39 (63)45 (72.6)17 (27.4)36 (58) < 2/10 HPF26 (42) ≥ 2/10 HPF32 (51.6) < 5 cm30 (48.4) ≥ 5 cm32 (51.6)30 (48.4)N/AN/AN/AYesSubtotal gastrectomy, complete tumor resection or segmental enterectomyYes (some of them)See comments
Imamura et al[8] N/AN/AN/AN/A55 (57.9) < 5/50 HPF40 (42.1) ≥ 5/50 HPF39 (41.05) < 5 cm56 (58.95) ≥ 5 cmN/AN/A1 (1.05)92 (96.85)2 (2.1)YesResection with negative marginsN/AN/A
Takahashi et al[23] N/AN/AN/AN/A33 (62.2) < 3/50 HPF20 (37.7) ≥ 3/50 HPF21 (39.6) ≤ 3 cm32 (60.3) > 3 cmN/AN/AN/AN/AN/AYesSurgical resectionN/AN/A
Waengertner et al[24] N/AN/AN/AN/AN/AN/AN/A, varies from 0.5 to 25 cm (median 4.8 cm)N/AN/AN/A57 (72.2%)N/AN/AN/AYesAdjuvant therapy with tyrosine kinase inhibitors (400mg/daily) for no longer than 3 months
Wang et al[9] N/AN/AN/AN/A45 (66.2) < 2/10 HPF23 (33.8) ≥ 2/10 HPF24 (35.3) ≤ 5 cm44 (64.7) > 5 cmN/AN/AN/AN/AN/AYesN/ANoNo
Zhao et al[25] N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A28 (22.58)73 (58.87)23 (18.55)YesOnly biopsy, palliative resection, radical resectionYesPostoperative